Table 1.
Characteristic of basic information.
| Author, year | Country | Total patients with RA | Age of RA(mean year ± SD) | Sex ratio of RA patients (M/F) | Duration of RA (mean year ± SD) | Source of control group | Number of control group | Study design | Quality score |
|---|---|---|---|---|---|---|---|---|---|
| E. Deseatnicova, 2022 (22) | Moldova | 59 | 54.2 ± 9.6 | NA | 9.6 ± 5.6 | Non-RA control | 48 | cross-section research | 1 |
| Nazary, K, 2021 (5) | Afghanistan | 400 | 36 ± 08 | 159/241 | 0 | Non-RA control | 400 | case-control study | 7 |
| Yadav, B., 2019 (23) | India | 493 | 47 ± 12 | 68/425 | 3.97 ± 3.93 | Osteoarthritis patients | 165 | cross-section research | 5 |
| Saqre, I. M., 2019 (24) | Egypt | 60 | 41 ± 10.5 | 17/43 | 8.6 ± 4.1 | Health control | 60 | case-control study | 6 |
| Li, Q., 2019 (11) | China | 65 | 59.58 ± 11.64 | 13/52 | 7.12 ± 8.58 | Health control | 550 | case-control study | 8 |
| Mahagna, H., 2018 (13) | Israel | 11782 | 61.1 ± 17.0 | 2679/9103 | NA | Non-RA control | 57973 | cross-section research | 4 |
| Huang, C. M., 2018 (25) | China | 18267 | 53.6 ± 13.9 | 3945/14322 | NA | Non-RA control | 73068 | case-control study | 6 |
| Guy, A., 2018 (26) | Israel | 15 | 56.27 ± 13.35 | 1/14 | NA | Health control | 32 | case-control study | 3 |
| Figueroa-Sánchez,2019 (27) | Mexico | 78 | 42.75 ± 12.15 | 13/65 | 4.74 ± 6.04 | Health control | 81 | cross-section research | 6 |
| El Achek, M. A., 2018 (28) | Tunisia | 111 | 51.04[18-80] | 17/94 | 6.54[0-29] | Ankylosing spondylitis patients | 60 | case-control study | 2 |
| Posselt, R. T., 2017 (29) | Brazil | 210 | 53.7 ± 10.45 | 19/191 | 11.1 ± 8.9 | Health control | 141 | cross-section research | 6 |
| Tascilar, K., 2016 (30) | Canada | 1357 | 63.7 ± 9.4 | 539/818 | 3.26 | Non-RA control | 13570 | case-control study | 6 |
| El-saadany, H., 2014 (31) | Egypt | 40 | 29.1 ± 6.1 | 0/40 | NA | Healthy female control | 20 | case-control study | 5 |
| Gomez, R., 2013 (32) | Colombia | 86 | 56.4 | 9/77 | NA | Arthropathy and fibromyalgia patients | 86 | case-control study | 5 |
| Acay, A., 2014 (33) | Turkey | 80 | 48.09 ± 10.25 | 17/63 | NA | Health control | 122 | cross-section research | 4 |
| McCoy, S. S., 2012 (14) | USA | 650 | 55.8 ± 15.7 | 202/448 | 7.9 ± 5.2 | Non-RA control | 650 | cohort study | 7 |
| Mousa, A. A., 2012 (34) | Egypt | 217 | 36.3 ± 12.8 | 43/174 | NA | Health control | 120 | case-control study | 6 |
| Fatima, F., 2010 (35) | India | 800 | 46.15 ± 13.37 | 132/668 | 4.9 ± 5.50 | Non-RA control | 800 | case-control study | 5 |
| Mobini, M., 2011 (36) | Iran | 80 | 51.4 ± 12 | 4/76 | NA | Osteoarthritis patients | 80 | case-control study | 5 |
| Przygodzka, M., 2009 (37) | Poland | 100 | 54 ± 12.2 | 0/100 | 12.3 | Non-RA control | 55 | case-control study | 7 |
| Haghighi, A., 2009 (38) | Iran | 75 | NA | 5/70 | NA | mechanical low back pain or osteoarthritis patients | 66 | case-control study | 2 |
| Al-Awadhi, A. M., 2008 (39) | Kuwait | 177 | 38.3 ± 12.8 | 37/140 | NA | Health control | 577 | cross-section research | 5 |
| Andonopoulos, A. P., 1996 (40) | Greece | 101 | 57,9 ± 13,5 | 29/72 | 8.3 ± 7.7 | Osteoarthritis patients | 70 | case-control study | 7 |
| Shiroky, J. B., 1993 (41) | Canada | 119 | NA | 28/91 | NA | Osteoarthritis or primary fibromyalgia patients | 108 | case-control study | 7 |
| Antonelli, A., 2006 (42) | Italy | 91 | 59 ± 16 | 1/91 | 9 ± 7 | Healthy female control | 180 | case-control study | 6 |
| Al-Awadhi, A. M., 1999 (43) | Kuwait | 48 | 47 ± 11 | 5/43 | NA | Non-inflammatory rheumatic diseases patients | 90 | case-control study | 7 |
| Innocencio, R. M., 2004 (44) | Brazil | 25 | 49 ± 13 | 7/18 | 18 ± 11 | Healthy blood donors | 113 | case-control study | 4 |
| Irena Kostic, 2006 (45) | Serbia | 24 | 54 ± 9 | 3/21 | 8.54 | Healthy blood donors | 34 | cross-section research | 4 |
| Maria José Santos, 2010 (46) | Portugal | 98 | 49.2 ± 13.7 | 0/98 | 7.6 | Healthy blood donors | 102 | case-control study | 6 |
RA, rheumatoid arthritis; USA, The United States of America. NA, Not Available.